Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Instructions to Redo Your Kona SUV for Improved Tasteful Allure and Usefulness - 2The most effective method to Go with Informed Choices on Vehicle Leases
- 3How to watch NASA's Artemis 2 astronauts launch to the moon on April 1
- 4EU waters down plans to end new petrol and diesel car sales by 2035
- 5Instructions to Pick the Right Toothbrush for Your Teeth
- Quantum Computing’s Next Major Breakthroughs Could Come From Australia
- Watch live as near-Earth asteroid Eros buzzes the Andromeda Galaxy on Nov. 30 (video)
- Merck urges science-led US vaccine schedule after CDC trims childhood vaccine list
- A Timeline of Rising Antisemitism in Australia
- Are multiverses real? An astrophysicist explains why it depends on how you define ‘real’
- A Concise History Of The Entertainment world
- Airbnb Unveils Airport Pickup Service Across 125 Cities in Global Expansion
- EU states agree first step for Ukraine reparations fund
- Instructions to Help a Friend or family member Determined to have Cellular breakdown in the lungs
